Figure 2.

Changes in sNfL (A) and sGFAP (B) levels induced by ocrelizumab. sNfL and sGFAP levels measured before (0M) and at 12 months (12M) of ocrelizumab initiation. Abbreviations: sNfL, serum neurofilament light chains; sGFAP, serum glial fibrillary acidic protein. ns: non-significant; NEDA-3, patients free of disease activity at 12 months of ocrelizumab initiation (n = 85); INFL, patients with new relapses and/or radiological activity during follow-up (n = 20); PIRA, patients who had confirmed disability progression in the absence of relapses or new MRI activity at 12 months of ocrelizumab initiation (n = 10).